CORDIS
EU research results

CORDIS

English EN
Bispecific monoclonal antibody technology concept

Bispecific monoclonal antibody technology concept

Objective

Monoclonal antibodies (mAbs) represent a new form of protein-based drug having demonstrated a significant impact on the treatment of several types of cancers.
Their specificity towards cell surface receptors makes them able to target and destroy tumour cells. However, a lot of progress is still necessary to understand the mechanism of binding and activity of antibodies in order to improve their targeting capabilities and their efficiency.
To reach these objectives, the BMC project proposes to:
- Develop a recombinant bispecific mAb with tetrameric binding sites, directed against two different antigens expressed on the same target tumour cell;
- Develop new bispecific or bifunctional molecules with the property of crosslinking two different receptors on the surface of the cell;
- Modify the carbohydrate moiety of bispecific antibodies and the tumour targeting of the complement regulator molecule, properdin, to trigger the activation of the complement enzymatic cascade at the tumour site.
The recombinant molecules are directed against a selected target antigen for mAb therapy, CDS, as well as a B-cell marker to be selected, in order to treat a specific type of leukaemia, the B-CLL. However, the described innovative cancer immunotherapy strategy will also be extended to the treatment of many other types of cancers especially all carcinomas.
The partnership gathers 9 partners recovering the needs of the BMC project:
- 7 RTDs specialized in genetic engineering (CNRS), innovative molecules design (UNIL), antibodies vectorisation with nanoparticles (HUJI), CDC activity improvement and cell lines and animal models development (GIENSAT), mechanisms of therapeutic antibodies on patients' cells (OORRBG), toxicology studies and standardization (ITEM);
- 2 biotechnology SMEs specialized in therapeutic antibodies development (MAT) and antibodies in-vitro production (MABGENE);
- A company dedicated to the project management until month 50: ALMA.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

FRAUNHOFER GESELLSCHAFT ZÜR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V

Address

Hansastrasse, 27 C
MÜNchen

Germany

Administrative Contact

Jürgen BORLAK (Professor)

Participants (8)

Sort alphabetically

Expand all

UNIVERSITÉ DE LAUSANNE

Switzerland

UNIVERSITÉ DE BRETAGNE OCCIDENTALE

France

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France

THE HEBREW UNIVERSITY OF JERUSALEM

Israel

AZIENDA OSPEDALIERA - OSPEDALI RIUNITI DI BERGAMO

Italy

MONOCLONAL ANTIBODIES THERAPEUTICS SAS

France

ALMA CONSULTING GROUP SAS

France

MABGENE SA

France

Project information

Grant agreement ID: 518185

  • Start date

    1 November 2005

  • End date

    30 June 2010

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 3 631 771

  • EU contribution

    € 2 450 000

Coordinated by:

FRAUNHOFER GESELLSCHAFT ZÜR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V

Germany